Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.

Nolte F, Nückel H, Schmidt B, Geer T, Rubanov O, Hebart H, Jarisch A, Albrecht S, Johr C, Schumann C, Hofmann WK.

J Cancer Res Clin Oncol. 2018 May 14. doi: 10.1007/s00432-018-2665-x. [Epub ahead of print]

PMID:
29761371
2.

HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia.

Wagner B, da Silva Nardi F, Schramm S, Kraemer T, Celik AA, Dürig J, Horn PA, Dührsen U, Nückel H, Rebmann V.

Cancer. 2017 Mar 1;123(5):814-823. doi: 10.1002/cncr.30427. Epub 2016 Nov 2.

3.

Shorter telomeres correlate with an increase in the number of uniparental disomies in patients with chronic lymphocytic leukemia.

Sellmann L, Scholtysik R, de Beer D, Eisele L, Klein-Hitpass L, Nückel H, Dührsen U, Dürig J, Röth A, Baerlocher GM.

Leuk Lymphoma. 2016;57(3):590-5. doi: 10.3109/10428194.2015.1076929. Epub 2015 Oct 12.

PMID:
26457386
4.

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC).

Haematologica. 2014 Aug;99(8):1285-91. doi: 10.3324/haematol.2013.101170.

5.

CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.

Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nückel H, Baldini L, Kurtova AV, Ferrajoli A, Burger JA, Gaidano G, Del Poeta G, Pepper C, Rossi D, Gattei V.

J Clin Oncol. 2014 Mar 20;32(9):897-904. doi: 10.1200/JCO.2013.50.8515. Epub 2014 Feb 10.

6.

Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.

Auel B, Goldschmidt H, Geer T, Moehler TM, Platzbecker U, Naumann R, Blau I, Hänel M, Knauf W, Nückel H, Salwender HJ, Scheid C, Weisel K, Gorschlüter M, Glasmacher A, Schmidt-Wolf IG; German Refractory Myeloma Study Group.

Indian J Hematol Blood Transfus. 2012 Jun;28(2):67-76. doi: 10.1007/s12288-011-0103-1. Epub 2011 Aug 18.

7.

Simple methods for the detection of HLA-G variants in coding and non-coding regions.

Nückel H, Castelli EC, Moreau P, Ochsenfarth C, Horn PA, Rebmann V.

Methods Mol Biol. 2012;882:123-42. doi: 10.1007/978-1-61779-842-9_7.

PMID:
22665231
8.

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany.

Stroet A, Hemmelmann C, Starck M, Zettl U, Dörr J, Friedemann P, Flachenecker P, Fleischer V, Zipp F, Nückel H, Kieseier BC, Ziegler A, Gold R, Chan A.

Ther Adv Neurol Disord. 2012 Mar;5(2):75-9. doi: 10.1177/1756285611433318. Erratum in: Ther Adv Neurol Disord. 2012 May;5(3):181. Paul, Friedmann [corrected to Friedemann, Paul].

9.

Prognostic significance of serum cystatin C in multiple myeloma.

Nückel H, Langer C, Herget-Rosenthal S, Wichert M, Assert R, Döhner H, Dührsen U, Liebisch P.

Int J Hematol. 2012 May;95(5):545-50. doi: 10.1007/s12185-012-1049-2. Epub 2012 Mar 18.

PMID:
22426688
10.

p53 protein expression in chronic lymphocytic leukemia.

Sellmann L, Carpinteiro A, Nückel H, Scholtysik R, Siemer D, Klein-Hipass L, Kube D, Dürig J, Dührsen U, Stanelle J, Küppers R.

Leuk Lymphoma. 2012 Jul;53(7):1282-8. doi: 10.3109/10428194.2011.654115. Epub 2012 Feb 13.

PMID:
22220854
11.

Excessive bilirubin elevation in a patient with hereditary spherocytosis and intrahepatic cholestasis.

Wree A, Canbay A, Müller-Beissenhirtz H, Dechêne A, Gerken G, Dührsen U, Lammert F, Nückel H.

Z Gastroenterol. 2011 Aug;49(8):977-80. doi: 10.1055/s-0031-1273368. Epub 2011 Aug 2.

PMID:
21811948
12.

Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model.

Aydin S, Grabellus F, Eisele L, Möllmann M, Hanoun M, Ebeling P, Moritz T, Carpinteiro A, Nückel H, Sak A, Göthert JR, Dührsen U, Dürig J.

Eur J Haematol. 2011 Jul;87(1):10-9. doi: 10.1111/j.1600-0609.2011.01626.x.

PMID:
21692849
13.

[Malignant epibulbar tumours: new strategies in diagnostics and therapy].

Westekemper H, Schallenberg M, Tomaszewski A, Nückel H, Sauerwein W, Meller D, Steuhl K.

Klin Monbl Augenheilkd. 2011 Sep;228(9):780-92. doi: 10.1055/s-0029-1246068. Epub 2011 Apr 12. Review. German.

PMID:
21487989
14.

Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme.

El Hindy N, Bachmann HS, Lambertz N, Adamzik M, Nückel H, Worm K, Zhu Y, Sure U, Siffert W, Sandalcioglu IE.

J Neurosurg. 2011 Jun;114(6):1631-9. doi: 10.3171/2010.12.JNS10478. Epub 2011 Jan 21.

PMID:
21250804
15.

Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.

Bachmann HS, Heukamp LC, Schmitz KJ, Hilburn CF, Kahl P, Buettner R, Nückel H, Eisenhardt A, Rübben H, Schmid KW, Siffert W, Eggert A, Schramm A, Schulte JH.

Int J Cancer. 2011 Nov 15;129(10):2390-9. doi: 10.1002/ijc.25904. Epub 2011 Mar 25.

16.

Telomeres and prognosis in patients with chronic lymphocytic leukaemia.

Sellmann L, de Beer D, Bartels M, Opalka B, Nückel H, Dührsen U, Dürig J, Seifert M, Siemer D, Küppers R, Baerlocher GM, Röth A.

Int J Hematol. 2011 Jan;93(1):74-82. doi: 10.1007/s12185-010-0750-2. Epub 2011 Jan 5.

PMID:
21203871
17.

Gene dosage effects in chronic lymphocytic leukemia.

Sellmann L, Scholtysik R, Kreuz M, Cyrull S, Tiacci E, Stanelle J, Carpinteiro A, Nückel H, Boes T, Gesk S, Siebert R, Klein-Hitpass L, Dührsen U, Dürig J, Küppers R.

Cancer Genet Cytogenet. 2010 Dec;203(2):149-60. doi: 10.1016/j.cancergencyto.2010.09.002.

PMID:
21156227
18.

[Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia].

Meyer C, Ansorge N, Siglienti I, Salmen S, Stroet A, Nückel H, Dührsen U, Ritter PR, Schmidt WE, Gold R, Chan A.

Nervenarzt. 2010 Dec;81(12):1483-9. doi: 10.1007/s00115-010-3041-5. German.

PMID:
21079910
19.

The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia.

Nückel H, Switala M, Sellmann L, Horn PA, Dürig J, Dührsen U, Küppers R, Grosse-Wilde H, Rebmann V.

Leukemia. 2010 Jun;24(6):1152-9. doi: 10.1038/leu.2010.74. Epub 2010 Apr 29.

PMID:
20428196
20.

The G-Allele of the PSMA6-8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels.

Bachmann HS, Novotny J, Sixt S, Liebisch P, Frey UH, Dührsen U, Siffert W, Nückel H.

Eur J Haematol. 2010 Aug;85(2):108-13. doi: 10.1111/j.1600-0609.2010.01455.x. Epub 2010 Apr 8.

PMID:
20408869
21.

Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia.

Johansson P, Eisele L, Klein-Hitpass L, Sellmann L, Dührsen U, Dürig J, Nückel H.

Leuk Res. 2010 Jul;34(7):892-8. doi: 10.1016/j.leukres.2010.02.038. Epub 2010 Mar 29.

PMID:
20353875
22.

Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer.

Heubner M, Wimberger P, Otterbach F, Kasimir-Bauer S, Siffert W, Kimmig R, Nückel H.

Int J Biol Markers. 2009 Oct-Dec;24(4):223-9.

PMID:
20082279
23.

A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.

Khandanpour C, Thiede C, Valk PJ, Sharif-Askari E, Nückel H, Lohmann D, Horsthemke B, Siffert W, Neubauer A, Grzeschik KH, Bloomfield CD, Marcucci G, Maharry K, Slovak ML, van der Reijden BA, Jansen JH, Schackert HK, Afshar K, Schnittger S, Peeters JK, Kroschinsky F, Ehninger G, Lowenberg B, Dührsen U, Möröy T.

Blood. 2010 Mar 25;115(12):2462-72. doi: 10.1182/blood-2009-08-239822. Epub 2010 Jan 14.

24.

Prognostic assessment of three single-nucleotide polymorphisms (GNB3 825C>T, BCL2-938C>A, MCL1-386C>G) in extrahepatic cholangiocarcinoma.

Fingas CD, Katsounas A, Kahraman A, Siffert W, Jochum C, Gerken G, Nückel H, Canbay A.

Cancer Invest. 2010 Jun;28(5):472-8. doi: 10.3109/07357900903095714.

PMID:
19968497
25.

BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia.

Zenz T, Benner A, Dührsen U, Dürig J, Döhner H, Siffert W, Stilgenbauer S, Nückel H.

Leuk Lymphoma. 2009 Nov;50(11):1837-42. doi: 10.3109/10428190903207530.

PMID:
19883311
26.

FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.

Nückel H, Collins CH, Frey UH, Sellmann L, Dürig J, Siffert W, Dührsen U.

Eur J Haematol. 2009 Dec 1;83(6):541-9. doi: 10.1111/j.1600-0609.2009.01328.x. Epub 2009 Aug 4.

PMID:
19682311
27.

BCL2-938C>A and CALCA-1786T>C polymorphisms in aseptic loosened total hip arthroplasty.

Wedemeyer C, Kauther MD, Hanenkamp S, Nückel H, Bau M, Siffert W, Bachmann HS.

Eur J Med Res. 2009 Jun 18;14(6):250-5.

28.

Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia.

Eisele L, Prinz R, Klein-Hitpass L, Nückel H, Lowinski K, Thomale J, Moeller LC, Dührsen U, Dürig J.

Eur J Haematol. 2009 Oct;83(4):320-7. doi: 10.1111/j.1600-0609.2009.01287.x. Epub 2009 Jun 2.

PMID:
19500131
29.

High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia.

Nückel H, Switala M, Collins CH, Sellmann L, Grosse-Wilde H, Dührsen U, Rebmann V.

Clin Immunol. 2009 Jun;131(3):472-80. doi: 10.1016/j.clim.2009.02.004. Epub 2009 Mar 24.

PMID:
19318232
30.

The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma.

Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nückel H, Lang S, Schmid KW, Siffert W, Bachmann HS.

Ann Oncol. 2009 Jun;20(6):1094-9. doi: 10.1093/annonc/mdn763. Epub 2009 Feb 5.

PMID:
19196738
31.

The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia.

Nückel H, Frey UH, Sellmann L, Collins CH, Dührsen U, Siffert W.

Br J Haematol. 2009 Jan;144(2):268-70. doi: 10.1111/j.1365-2141.2008.07442.x. Epub 2008 Nov 11. No abstract available.

PMID:
19016725
32.

Significantly shorter telomeres in T-cells of patients with ZAP-70+/CD38+ chronic lymphocytic leukaemia.

Röth A, de Beer D, Nückel H, Sellmann L, Dührsen U, Dürig J, Baerlocher GM.

Br J Haematol. 2008 Nov;143(3):383-6. doi: 10.1111/j.1365-2141.2008.07363.x. Epub 2008 Aug 28.

PMID:
18759763
33.

Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.

Ortmann CA, Eisele L, Nückel H, Klein-Hitpass L, Führer A, Dührsen U, Zeschnigk M.

Ann Hematol. 2008 Oct;87(10):809-18. doi: 10.1007/s00277-008-0514-8. Epub 2008 Jun 28.

PMID:
18587578
34.

The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.

Bachmann HS, Otterbach F, Callies R, Nückel H, Bau M, Schmid KW, Siffert W, Kimmig R.

Clin Cancer Res. 2007 Oct 1;13(19):5790-7.

35.

HLA-G in B-chronic lymphocytic leukaemia: clinical relevance and functional implications.

Rebmann V, Nückel H, Dührsen U, Grosse-Wilde H.

Semin Cancer Biol. 2007 Dec;17(6):430-5. Epub 2007 Jun 28. Review.

PMID:
17683947
36.

Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia.

Sellmann L, Gesk S, Walter C, Ritgen M, Harder L, Martín-Subero JI, Schroers R, Siemer D, Nückel H, Dyer MJ, Dührsen U, Siebert R, Dürig J, Küppers R.

Br J Haematol. 2007 Jul;138(2):217-20.

PMID:
17593029
37.
38.

No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia.

Riemann K, Becker L, Struwe H, Nückel H, Dührsen U, Alakus H, Winde G, Neuhäuser M, Rübben H, Schmitz KJ, Wohlschlaeger J, Schmid KW, Siffert W.

Pharmacogenet Genomics. 2006 Nov;16(11):783-8.

PMID:
17047486
39.

The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia.

Frey UH, Nückel H, Sellmann L, Siemer D, Küppers R, Dürig J, Dührsen U, Siffert W.

Clin Cancer Res. 2006 Oct 1;12(19):5686-92.

40.

Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia.

Nückel H, Frey UH, Bau M, Sellmann L, Stanelle J, Dürig J, Jöckel KH, Dührsen U, Siffert W.

Blood. 2007 Jan 1;109(1):290-7. Epub 2006 Sep 7.

41.

Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status.

Hüttmann A, Klein-Hitpass L, Thomale J, Deenen R, Carpinteiro A, Nückel H, Ebeling P, Führer A, Edelmann J, Sellmann L, Dührsen U, Dürig J.

Leukemia. 2006 Oct;20(10):1774-82. Epub 2006 Aug 17.

PMID:
16932341
42.

Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia.

Nückel H, Hüttmann A, Klein-Hitpass L, Schroers R, Führer A, Sellmann L, Dührsen U, Dürig J.

Leuk Lymphoma. 2006 Jun;47(6):1053-61.

PMID:
16840197
43.

Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia.

Novotny JR, Nückel H, Dührsen U.

Eur J Haematol. 2006 Apr;76(4):299-308.

PMID:
16519701
44.

Bax gene G(-248)A promoter polymorphism and chronic lymphocytic leukemia: lack of association with incidence, disease stage and progression-free survival.

Nückel H, Frey UH, Sellmann L, Bau M, Dürig J, Dührsen U, Siffert W.

Leukemia. 2006 Apr;20(4):724. No abstract available.

PMID:
16453002
45.

Detection of malignant haematopoietic cells in the cerebrospinal fluid by conventional cytology and flow cytometry.

Nückel H, Novotny JR, Noppeney R, Savidou I, Dührsen U.

Clin Lab Haematol. 2006 Feb;28(1):22-9.

PMID:
16430456
46.

Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure--Feasibility, safety and effects on exercise tolerance and cardiac function.

Hüttmann A, Dührsen U, Stypmann J, Noppeney R, Nückel H, Neumann T, Gutersohn A, Nikol S, Erbel R.

Basic Res Cardiol. 2006 Jan;101(1):78-86. Epub 2005 Oct 21.

PMID:
16237506
47.

Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study.

Müller-Beissenhirtz H, Kasper C, Nückel H, Dührsen U.

Ann Hematol. 2005 Nov;84(12):796-801. Epub 2005 Nov 12.

PMID:
16041531
48.
49.

Quantification of G protein Gaalphas subunit splice variants in different human tissues and cells using pyrosequencing.

Frey UH, Nückel H, Dobrev D, Manthey I, Sandalcioglu IE, Eisenhardt A, Worm K, Hauner H, Siffert W.

Gene Expr. 2005;12(2):69-81.

PMID:
15892449
50.

HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia.

Nückel H, Rebmann V, Dürig J, Dührsen U, Grosse-Wilde H.

Blood. 2005 Feb 15;105(4):1694-8. Epub 2004 Oct 5.

Supplemental Content

Loading ...
Support Center